Bladder pain syndrome (BPS) is defined as a persistent or recurrent chronic pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by at least one other urinary symptom such as an urgent need to void or urinary frequency. The duration must be 6 month or more.  Reports of BPS prevalence have varied greatly, along with the diagnostic criteria and populations studied. Recent reports range from 0.06 to 30% with female predominance and is a disease that negatively impacts quality of life with more anxiety, depression, and psychosocial setbacks than aged-matched controls.

We are conducting a small-scale study with Pentosan polysulfate which already is approved and marketed as treatment to patients diagnosed with BPS. The purpose of this small-scale study is to evaluate the feasibility of pentosan polysulfate in the treatment of BPS prior to full-scale implementation of the treatment in a clinical setting. Patients are treated three times a day for 6 month and are followed 9 months in total.